NF2 and meningioma: The phase II CEVOREM trial (NCT02333565) combined octreotide, a somatostatin analog, with everolimus for the treatment of aggressive and otherwise treatment-refractory meningiomas, although only 4 of the 20 patients had a germline NF2 mutation.